Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company''s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
最新股票文章
日圓走勢預測：第三方價格目標
2025年截至目前，美元兌日圓（USD/JPY）匯率年內下跌約9.41%。2025年4月25日，日圓兌美元收於142.8790，創下自2024年9月以來的最強水平之一，較2024年7月的高點161.942下跌約11.77%。
11:17, 19 6月 2025
黃金價格走勢分析2025：第三方目標與市場預測
黃金一直被視為經濟不確定時期的重要避險資產。隨著2025年受中央銀行政策轉向、通脹壓力變化以及地緣政治緊張局勢的影響，黃金在交易圈中仍然備受關注。
21:45, 28 4月 2025
評級和評論
評級和評論
